SciELO - Scientific Electronic Library Online

vol.30 número4Compliance with the treatment Implications of non-compliance. Hot TopicTakayasu's arteritis in a 15 year old girl índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados




Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google


Acta Medica Colombiana

versão impressa ISSN 0120-2448


SILVA, Federico; RUEDA-CLAUSEN, Christian  e  ARDILA, Yenny. Resistance to (ASA). A challenge in the therapeutic approach of patients at high cardio-cerebral-vascular risk. Acta Med Colomb [online]. 2005, vol.30, n.4, pp.274-280. ISSN 0120-2448.

Acetyl salycilic acid (ASA) has demonstrated beneficial effects in the management of subjects with increased risk of thromboembolism. Previous studies has proposed that an important number of subjects have a sub-optimal anti-aggregate response to this drug and higher risk of presenting an atherotrombotic episode, even while receiving the appropriate dose. Multiple etiologies have been proposed to explain this situation to which different farmacodynamic and farmacoquinetic entities could be related. There is no consensus about atherothrombotic the most appropriate technique to assess platelets' response to the ASA, the prevalence of this entity has not been determined. Even though, this resistance might be suspected in every subject with an atherothrombotic episode when receiving adequate dosage of ASA. The appropriated diagnosis and treatment of these of entities can turn into a real challenge. The aim of this study is to review the origin and recent diagnostic methods, classifications, and therapeutic alternatives for ASA resistance.

Palavras-chave : acetil salycilic acid; resistance; aspirin; cardiovascular disease.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )


Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons